Browse > Article

Study of Efficacy and Safety of Tianwangbuxin-dan for Poststroke Depression: A Randomized, Double Blinded, Non-inferiority Trial  

Lee, Il-Suk (Dept. of Internal Medicine and Neuroscience, College of Korean Medicine, Won-Kwang University)
Kim, Mun-Soo (Dept. of Psychology, College of Social Science, Chon-Nam National University)
Lee, Sang-Kwan (Dept. of Internal Medicine and Neuroscience, College of Korean Medicine, Won-Kwang University)
Publication Information
The Journal of Internal Korean Medicine / v.35, no.2, 2014 , pp. 145-156 More about this Journal
Abstract
Objectives : The aim of this study was to compare Tianwangbuxin-dan to Fluoxetine for antidepressive efficacy and safety in poststroke depression (PSD). Methods : A randomized, double blinded, non-inferiority trial was conducted. 113 PSD patients were recruited from a stroke center. Except for the 25 excluded patients, 88 PSD patients were randomly given either Tianwangbuxin-dan 1100 mg or Fluoxetine 20 mg per a day for 16 weeks. PSD was evaluated using Beck's depression inventory (BDI) and Hamilton depression rating scale (HDRS) and followed every fourth week. Repeated measure analysis of variance (ANOVA) was used to compare and contrast the depression scores of the two groups and to compare them among the evaluation times, at the beginning, $4^{th}$, $8^{th}$, $12^{th}$ and $16^{th}$ weeks. In addition, independent t-tests were used to find the difference between two groups at every evaluation time. Results : Finally, 88 PSD patients were included in the study, 63 PSD patients completed the procedure and 25 PSD patients were dropped out by the incompliance or withdrawal of consent. Tianwangbuxin-dan (or Fluoxetine) improved the depression of stroke patients and the efficacy of Tianwangbuxin-dan was not inferior to that of Fluoxetine. In addition, there was no significant side effect in two groups. Conclusions : This study showed that antidepressive efficacy and safety of Tianwangbuxin-dan in PSD patients.
Keywords
Tianwangbuxin-dan; Fluoxetine; poststroke depression; Beck's depression inventory; Hamilton depression rating scale;
Citations & Related Records
Times Cited By KSCI : 7  (Citation Analysis)
연도 인용수 순위
1 Spalletta G, Guida G, De Angelis D, Caltagirone C. Predictors of cognitive level and depression severity are different in patients with left and right hemispheric stroke within the first year of illness. J Neurol 2002;249(11):1541-51.   DOI   ScienceOn
2 Kauhanen ML, Korpelainen J, Hiltunen P, Maatta R, Mononen H, Brusin E, et al. Aphasia, depression, and non-verbal cognitive impairment in ischaemic stroke. Cerebrovasc Dis 2000;10(6):455-61.   DOI   ScienceOn
3 Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 2003;54(3):376-87.   DOI   ScienceOn
4 House A, Dennis M, Warlow C, Hawton K, Molyneux A. The relationship between intellectual impairment and mood disorder in the first year after stroke. Psychol Med 1990;20(4):805-14.   DOI
5 Wiart L, Petit H, Joseph P, Mazaux J, Barat M. Fluoxetine in Early Poststroke Depression A Double-Blind Placebo-Controlled Study. Stroke 2000;31(8):1829-32.   DOI   ScienceOn
6 Paolucci S, Antonucci G, Grasso MG, Morelli D, Troisi E, Coiro P, et al. Post-stroke depression, antidepressant treatment and rehabilitation results. Cerebrovasc Dis 2001;12(3):264-71.   DOI   ScienceOn
7 Lipsey J, Pearlson G, Robinson R, Rao K, Price T. Nortriptyline treatment of post-stroke depression: a double-blind study. The Lancet 1984;323(8372):297-300.   DOI   ScienceOn
8 Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25(6):1099-104.   DOI   ScienceOn
9 Chemerinski E, Robinson RG, Kosier JT. Improved recovery in activities of daily living associated with remission of poststroke depression. Stroke 2001;32(1):113-7.   DOI   ScienceOn
10 Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011;10(2):123-30.   DOI   ScienceOn
11 Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and poststroke depression: a placebocontrolled trial of antidepressants. Am J Psychiatry 2003;160(10):1823-9.   DOI   ScienceOn
12 Yi Z, Liu F, Zhai S. Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta‐analysis. Int J Clin Pract 2010;64(9):1310-7.   DOI   ScienceOn
13 Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA 2008;299(20):2391-400.   DOI   ScienceOn
14 Chen W, Liu F, Yang A. Study of effect of integrative Chinese herbs with fluoxetine on rehabilitation of neurological impairment in patients with post-stroke depression. Journal of Chengdu University of Traditional Chinese Medicine 2001;24(4):20.
15 Stamenkovic M, Schindler S, Kasper S. Therapy of post-stroke depression with fluoxetine. A pilot project. Nervenarzt 1996;67(1):62-7.
16 Mead GE, Hsieh CF, Lee R, Kutlubaev M, Claxton A, Hankey GJ, et al. Selective Serotonin Reuptake Inhibitors for Stroke Recovery A Systematic Review and Meta-analysis. Stroke 2013;44(3):844-50.   DOI   ScienceOn
17 Li LT, Wang SH, Ge HY, Chen J, Yue SW, Yu M. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) and fluoxetine on post-stroke depression. J Altern Complement Med 2008;14(7):841-6.   DOI   ScienceOn
18 Gonzalez-Torrecillas JL, Mendlewicz J, Lobo A. Effects of early treatment of poststroke depression on neuropsychological rehabilitation. Int Psychogeriatr 1995;7(04):547-60.   DOI   ScienceOn
19 Paolucci S. Epidemiology and treatment of post-stroke depression. Neuropsychiatr Dis Treat 2008;4(1):145.
20 Murray V, Arbin Mv, Bartfai A, Berggren AL, Landtblom AM, Lundmark J, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry 2005;66(6):708-16.   DOI
21 Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000;157(3):351-9.   DOI   ScienceOn
22 이상택, 김근우, 구병수. 삼정환 (三精丸) 의 항우울 효과에 대한 실험적 연구. 동의신경정신과학회지 2008;19(3):101-15.
23 선종주, 정세연, 황재웅, 김석민, 정재한, 최창민, 등. 중풍후우울증 환자에 대한 향기침요법의 임상적 연구. 대한한방내과학회지 2006;27(2):480-7.
24 강형원, 장현호, 강인선, 문형철, 황유진, 유영수. 우울증(憂鬱症) 의 한방적(韓方的) 이해(理解)에 관한 문헌고찰(文獻考察). 동의신경정신과학회지 2001;12(2):1-15.
25 이일석, 박기언, 홍해진, 송인자, 성강경, 이상관. 뇌졸중 후 우울증과 한열허실 변증의 상관관계. 대한한방내과학회지 2014;35(1):50-8.
26 최지혜, 김래희, 윤종민, 문병순. 뇌졸중후 우울증 침치료의 임상연구에 대한 고찰. 동의생리병리학회지 2011;25(6):1119-28.
27 제준태, 이상관. 뇌졸중 후 우울증에 대한 황련 해독탕 약침의 안전성 및 유효성 평가를 위한 임상 시험. 대한약침학회지 2010;13(2):67-73.
28 Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4(6):561.   DOI   ScienceOn
29 나병조, 정재한, 최창민, 홍진우, 김태훈, 이준우, 등. 중풍후우울증에 대한 반하후박탕의 유효성 및 적응증 평가. 대한한방내과학회지 2005;26(3):563-74.
30 Youn JI, Sung KK, Song BK, Kim M, Lee S. Effects of Electro-Acupuncture Therapy on Post-Stroke Depression in Patients with Different Degrees of Motor Function Impairments: a Pilot Study. J Phys Ther Sci 2013;25(6):725.   DOI   ScienceOn
31 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23(1):56.   DOI
32 Choi-Kwon S, Han SW, Kwon SU, Kang DW, Choi JM, Kim JS. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness a double-blind, placebocontrolled study. Stroke 2006;37(1):156-61.   DOI   ScienceOn
33 Weng S, Tang J, Wang G, Wang X, Wang H. Comparison of the Addition of Siberian Ginseng (Acanthopanax senticosus) Versus Fluoxetine to Lithium for the Treatment of Bipolar Disorder in Adolescents: A Randomized, Double-Blind Trial. Current Therapeutic Research 2007;68(4):280-90.   DOI   ScienceOn
34 허준. (對譯)東醫寶鑑. 서울: 법인문화사; 1999, p. 205.
35 식품의약품안전처. 천심액(천왕보심단) [cited 1998 Oct 21]. Available from: http://ezdrug.mfds.go.kr/kfda2.
36 식품의약품안전처. 푸로작캡슐20밀리그램(플루옥세틴염산염) [cited 2005 Dec 17]. Available from: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200409973.
37 危亦林. 世醫得效方. 서울: 醫聖堂; 1990, p. 217.
38 呂光榮. 中醫腦病證治. 북경: 과학기술문헌출판사; 1991, p. 72-81.
39 박종흠, 배창욱, 전현숙, 홍성유, 박선동. 천왕보심단(天王補心丹)의 항우울효과 및 monoamine 대사에 미치는 영향. 대한한의학방제학회지 2004;12(2):77-93.
40 Chen Q. The Clinical and pharmacology of the Chinese patent medicine. Beijing: Ren Min Wei Min Chu Ban She; 1998, p. 342-59.
41 김남재, 공영윤, 장순욱. 생약복합제제(生藥複合製劑)의 약효연구(藥效硏究)(제37보)(第37報)-천왕보심단(天王補心丹)이 중추신경계(中樞神經系) 및 순환기계(循環器系) 에 미치는 영향(影響). 생약학회지 1988;19(3):208-15.
42 Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fluoxetine treatment of post-stroke depression. J Neurol 2003;250(3):347-51.   DOI   ScienceOn
43 Huffman J, Stern TA. Acute psychiatric manifestations of stroke: a clinical case conference. Psychosomatics 2003;44(1):65-75.   DOI   ScienceOn
44 Robinson RG, Spalletta G. Poststroke depression: a review. Can J Psychiatry 2010;55(6):341.   DOI